Drug intelligence / Profile preview

TD02-OVL5

Development stage: Preclinical
Lead developer: Tissue Dynamics
Modality: Small Molecules

Overview

TD02-OVL5 is a first-in-class investigational drug targeting UBL5 (ubiquitin-like protein 5), developed for the treatment of obesity and metabolic diseases. It acts as a modulator of UBL5, a protein implicated in metabolic regulation. The drug was initially developed by Tissue Dynamics and is being advanced in partnership with Novo Nordisk. As of May 2025, its highest development status is preclinical. The primary therapeutic area is endocrinology and metabolic disease, specifically obesity[1][2][3].

Targets

UBL5 (Ubiquitin-like protein 5)

Beyond the preview

Go deeper on TD02-OVL5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TD02-OVL5.

Explore the full profile